Wingspan Announces its eTMF for Official Electronic Trial Master File has Been Selected by Europe's Largest Biopharmaceutical Company

Article

Company News Release

Wingspan announces that Actelion Pharmaceuticals, a top 20 biopharmaceutical company, has selected Wingspan eTMF as its official electronic trial master file.

Wingspan announces that Actelion Pharmaceuticals, a top 20 biopharmaceutical company, has selected Wingspan eTMF as its official electronic trial master file. The company, based in Switzerland, outlined specific goals of the trial master file implementation including providing key management metrics, increasing inspection readiness, saving time, reducing costs and increasing eTMF quality. Wingspan eTMF allows Actelion access to comprehensive metrics and reports in real time and integrates with the company’s existing applications. Because Wingspan eTMF is cloud-based, Actelion’s clinical trial specialists will have 24-hour access to trial related documents managed by Wingspan eTMF and easy external access from any location for all users, including CROs and partners.

Additionally, Actelion selected Wingspan given the technology company’s specialized focus on eTMF and strong client references from Pfizer and ICON, plc.

Wingspan Principal and CEO, Troy Deck said, "We are thrilled to have Actelion as a client and extraordinarily excited to be able to support their worldwide research through the use of our eTMF platform. Wingspan’s technical excellence and focus on trial efficiency aligns well with Actelion’s core values of Innovation and Results-Driven approach. Working together, we will continue to shape and improve the TMF landscape through refinement and expansion of our powerful and distinct capabilities."

After signing contractual agreements last week, Wingspan project managers joined the Actelion team in Switzerland to kick-off the implementation project. Wingspan will work with Actelion to launch its pilot project in mid-February with a larger rollout in June.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.